Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results
August 18, 2022 07:00 ET
|
Quoin Pharmaceuticals, Inc.
Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton SyndromeExpands number of commercial partnerships to eight, covering 60 countriesSigns Research Agreement to develop a...
Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th
August 11, 2022 16:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering
August 09, 2022 16:23 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering
August 05, 2022 09:28 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in Europe
July 28, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., July 28, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements
July 15, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., July 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has...
Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study
July 06, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., July 06, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases,...
Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
June 15, 2022 16:01 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China
June 15, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University
May 23, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., May 23, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...